Treatment of depression in patients with comorbid somatic diseases


DOI: https://dx.doi.org/10.18565/therapy.2020.3.76-83

Rukavishnikov G.V., Neznanov N.G., Martynov A.I., Mazo G.E.

1 National medical research Center of psychiatry and neurology named after V.M. Bekhterev of the Ministry of Healthcare, Saint Petersburg; 2 First Pavlov State medical University of Saint Petersburg of the Ministry of Healthcare of Russia; 3 A.I. Yevdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia
Various medical specialists regularly face the problem of optimal antidepressant therapy selection in patients with comorbid mental and somatic pathology. The aim of our review: to evaluate the aspects of the treatment of depression in various types of somatic diseases, focusing primarily on the safety issues. This review discusses the main aspects of antidepressant therapy in patients with cardiovascular, metabolic, gastrointestinal and oncological diseases.
In most cases, antidepressant therapy in patients with comorbid somatic diseases is a necessary and effective objective for stabilizing both mental and somatic problems and improving the overall prognosis. At the same time, before starting treatment, each case should be assessed by the attending physician individually, taking into account all aspects that may affect the quality of therapy and the patient’s condition.
Keywords: antidepressive treatment, oncological diseases, gastrointestinal diseases, comorbidity, depression, cardiovascular diseases, diabetes
Read entire article

Literature


  1. Депрессия и риск развития соматических заболеваний: руководство для врачей. Под ред. Н.Г. Незнанова, Г.Э. Мазо, А.О. Кибитова. М.: Специальное издательство медицинских книг, 2018; 248 с.

  2. Смулевич А.Б., Дубницкая Э.Б., Воронова Е.И. К проблеме распознавания психосоматических расстройств в общемедицинской практике. Психические расстройства в общей медицине. 2017; 3–4: 4–10. [Smulevich A.B., Dubnitskaya E.B., Voronova E.I. To the problem of recognition of psychosomatic disorders in general medical practice. Psikhicheskie rasstroystva v obschey medicine. 2017; 3–4: 4–10 (In Russ.)].

  3. Stover E., Fenton W., Rosenfeld A., Insel T. Depression and comorbid medical illness: the National Institute of Mental Health perspective. Biol. Psychiatry. 2003; 54: 184–86.

  4. Незнанов Н.Г., Кибитов А.О., Рукавишников Г.В., Мазо Г.Э. Прогностическая роль депрессии в качестве предиктора манифестации хронических соматических заболеваний. Терапевтический архив. 2018; 90(12): 122–32. [Neznanov N.G., Kibitov A.O., Rukavishnikov G.V. et al. The prognostic role of depression as a predictor of chronic somatic diseases manifestation. Terapevticheskiy arkhiv. 2018; 90(12): 122–32 (In Russ.)]. doi: 10.26442/00403660.2018.12.000019.

  5. Рукавишников Г.В., Кибитов А.О., Мазо Г.Э., Незнанов Н.Г. Генетическая детерминированность коморбидности депрессии и соматических заболеваний. Журнал неврологии и психиатрии им. C.C. Корсакова. 2019; 119(1): 89–96. [Rukavishnikov G.V., Kibitov A.O., Mazo G.E. et al. Genetic comorbidity of depression and somatic disorders. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2019; 119(1): 89–96 (In Russ.)]. doi: 10.17116/jnevro201911901189.

  6. Психосоматические расстройства в клинической практике (под ред. А.Б. Смулевича). М.: МЕДпресс-информ, 2016; 776 с.

  7. Rayner L., Price A., Evans A. et al. Antidepressants for depression in physically ill people. Cochrane Database Syst Rev. 2010 Mar 17; 3: CD007503. doi: 10.1002/14651858.CD007503.pub2.

  8. Zhang Y., Chen Y., Ma L. Depression and cardiovascular disease in elderly: Current understanding. J Clin Neurosci. 2018 Jan; 47: 1–5. doi: 10.1016/j.jocn.2017.09.022.

  9. Teply R.M., Packard K.A., White N.D. et al. Treatment of depression in patients with concomitant cardiac disease. Progress in Cardiovascular Diseases. 2016. 58(5): 514–28. doi: https://doi.org/10.1016/j.pcad.2015.11.003.

  10. Иванов С.В., Волель Б.А., Сыркина Е.А. с соавт. Ретроспективное архивное исследование по оценке безопасности применения современных антидепрессантов в кардиологической практике. Терапевтический архив (архив до 2018 г.). 2017; 89(12): 34–42. [Ivanov S.V., Volel B.A., Syrkina E.A. et al. A retrospective historical study evaluating the safe use of current antidepressants in cardiology practice. Terapevticheskiy arkhiv. 2017; 89(12): 34–42 (In Russ)]. doi: https://doi.org/10.17116/terarkh2017891234-42

  11. Licht C.M., de Geus E.J., Seldenrijk A. et al. Depression is associated with decreased blood pressure, but antidepressant use increases risk for hypertension. Hypertension. 2009; 52: 631–38. doi: 10.1161/HYPERTENSIONAHA.108.126698.

  12. Dowlati Y., Herrmann N., Swardfager W.L. et al. Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: a meta-analysis. Can J Psychiatry. 2010; 55(2): 91–98.

  13. Pizzi C., Rutjes A.W.S, Costa G.M. et al. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011; 107: 972–79. doi: 10.1016/j.amjcard.2010.11.017.

  14. Diez-Quevedo C., Lupon J., Gonzalez B. et al. Depression, antidepressants, and long-term mortality in heart failure. In J Cardiol. 2013; 167: 1217–25. doi: 10.1016/j.ijcard.2012.03.143.

  15. Castro V.M., Clements C.C., Murphy S.N. et al. QT interval and antidepressant use: a cross-sectional study of electronic health records. Br Med J. 2013; 346: f288. doi: 10.1136/bmj.f288.

  16. Beach S.R., Kostis W.J., Celano C.M. et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry. 2014; 75(5): 441–49. doi: 10.4088/JCP.13r08672.

  17. Dent L.A., Orrock M.W. Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy. 1997; 17: 170–72.

  18. De Abajo F.J., Garcia-Rodriguez L.A. Risk of upper gastrointestinal tract bleedings associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry. 2008; 65: 795–803. doi: 10.1001/archpsyc.65.7.795.

  19. Hirsh/Rokach C., Spectre G., Shai et al. Differential impact of selective serotonin reuptake inhibitors on platelet response to clopidogrel: a randomized, double-blind, crossover trial. Pharmacother 2015; 35(2): 140–47. doi: 10.1002/phar.1542.

  20. Labos C., Dasgupta K., Nedjar H. et al. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. Can Med Assoc J. 2011; 183(6): 1835–43. doi: 10.1503/cmaj.100912.

  21. Walley T., Pirmohamed M., Proudlove C., Maxwell D. Interaction of metoprolol and fluoxetine. Lancet. 1993; 341: 967–68.

  22. Sternbach H. Fluoxetine-associated potentiation of calcium-channel blockers. J Clin Psychopharmacol. 1991; 11: 390–91.

  23. Sartorius N. Depression and diabetes. Dialogues Clin Neurosci. 2018; 20(1): 47–52.

  24. Zimmermann U., Kraus T., Himmerich H. et al. implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res. 2003; 37: 193–220.

  25. Yoon J.M., Cho E.G., Lee H.K., Park S.M. Antidepressant use and diabetes mellitus risk: A meta-analysis. Korean Journal of Family Medicine. 2013; 34(4): 228–40. doi: https://doi.org/10.4082/kjfm.2013.34.4.228

  26. Khazaie H., Rahimi M., Tatari F. et al. Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram? Neurosciences. 2011; 16: 42–45.

  27. Gagnon J., Lussier M.-T., MacGibbon B. et al. The impact of antidepressant therapy on glycemic control in Canadian primary care patients with diabetes mellitus. Frontiers in Nutrition. 2018; 5: 47. doi: https://doi.org/10.3389/fnut.2018.00047.

  28. Markowitz S., Gonzalez J.S., Safren S.A. Treating depression in diabetes : emerging findings. Psychosomatics. 2011; 52(1): 1–18. doi: https://doi.org/10.1016/j.psym.2010.11.007.Treating

  29. An L., Ravindran P.P., Renukunta S., Denduluri S. Co-medication of pravastatin and paroxetine-a categorical study. J Clin Pharmacol. 2013 Nov; 53(11): 1212–19. doi: 10.1002/jcph.151

  30. Tatonetti N.P., Denny J.C., Murphy S.N. et al. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels // Clin Pharmacol Ther. 2011; 90(1): 133–42. doi: 10.1038/clpt.2011.83

  31. Gooden K.M., Bibeau K.B., Wood J. et al. Incidence of type 2 diabetes among patients exposed to the combination of pravastatin and paroxetine. Curr Drug Saf. 2015; 10(2): 152–58.

  32. Depression and Diabetes. Wayne Katon, Mario Maj, Norman Sartorius. John Wiley & Sons. Jun 9, 2011. Medical. 192 p.

  33. Neuendorf R., Harding A., Stello N. et al. Depression and anxiety in patients with inflammatory bowel disease: a systematic review. J Psychosom Res. 2016 Aug; 87: 70–80. doi: 10.1016/j.jpsychores.2016.06.001.

  34. Thiwan S.I. M., Drossman D.A. Treatment of functional GI disorders with psychotropic medicines: A review of evidence with a practical approach. Gastroenterology and Hepatology. 2006; 2(9): 678–88.

  35. Ostuzzi G., Matcham F., Dauchy S. et al. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2018; 4(4): CD011006. doi: 10.1002/14651858.CD011006.pub3.

  36. Depression and Cancer. David W. Kissane, Mario Maj, Norman Sartorius. John Wiley & Sons. Jul 7, 2011. Medical. 258 p.

  37. Scarborough B.M., Smith C.B. Optimal pain management for patients with cancer in the modern era. CA Cancer J Clin. 2018; 68(3): 182–96. doi: 10.3322/caac.21453.

  38. Desmarais J.E., Looper K.J. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry. 2009 Dec; 70(12): 1688–97. doi: 10.4088/JCP.08r04856blu.


About the Autors

Grigory V. Rukavishnikov, PhD, researcher of the Department of endocrinological psychiatry of National medical research Center of psychiatry and neurology named after V.M. Bekhterev of the Ministry of Healthcare of Russia. Address: 192019, Saint Petrsburg, 3 Bekhtereva Str. E-mail: grigory_v_r@mail.ru. ORCID: 0000-0002-5282-2036; SPIN-код: 6859-8787
Nikolay G. Neznanov, MD, professor, Director and scientific leader of the Department of geriatric psychiatry, head of the Department of psychiatry and narcology of First Pavlov State medical University of Saint Petersburg of the Ministry of Healthcare of Russia. Address: 192019, Saint Petrsburg, 3 Bekhtereva Str. E-mail: spbinstb@bekhterev.ru.
ORCID: 0000-0001-5618-4206; SPIN-код: 9772-0024
Anatoly I. Martynov, MD, academician of RAS, professor of the Department of hospital therapy No 1 of A.I. Yevdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia, President of Russian Scientific Medical Society of Therapists. Address: 127473, Moscow, 20/1 Delegatskaya Str. E-mail: anatmartynov@mail.ru. SPIN-код: 5271-3173
Galina E. Mazo, MD, academic secretary, scientific leader of the Department of endocrinological psychiatry of National medical research Center of psychiatry and neurology named after V.M. Bekhterev of the Ministry of Healthcare of Russia. E-mail: galina-mazo@yandex.ru. ORCID: 0000-0001-7910-9129; SPIN-код: 1361-6333


Similar Articles

Back to Content

Бионика Медиа